Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets.
The partnership is set to progress the discovery and development of new therapeutic solutions that target G protein-coupled receptors (GPCRs), transporters and ion channels, which are crucial in cardio-renal-metabolic and mental health diseases.
Go deeper with GlobalData
Salipro platform technology will be leveraged in the partnership. This platform stabilises membrane proteins in their native states, facilitating their usage in drug discovery programmes.
It brings together Salipro Biotech’s expertise and its platform technology for stabilising targets from the drug discovery programmes of Boehringer, enabling and expediting the development of new therapeutics.
Boehringer plans to carry out structural and biophysical studies which include cryo-electron microscopy on its pipeline targets to detect potential candidates.
Boehringer will provide Salipro with research and option payments.
Salipro is qualified for success-based milestone payments contingent on the developmental outcomes produced by Boehringer under this partnership.
Salipro Biotech CEO Jens Frauenfeld stated: “We are excited to collaborate with the innovative teams at Boehringer Ingelheim.
“By combining our Salipro platform technology with Boehringer Ingelheim’s expertise in biophysical and structural studies, we enable new possibilities in drug discovery and development.”
The Swedish company has established several research partnerships with pharmaceutical and biotech entities. It aims to expedite drug discovery via in-house and collaborated pipelines.
In December 2024, the company announced the receipt of patents granted for its Salipro platform technology in both Australia and Singapore.
It also facilitates drug discovery programmes, which include screening small molecule drugs, structure-based drug design and antibody discovery.
In October 2023, Salipro Biotech entered a multi-target antibody research agreement with Icosagen, a biotech company.
